Clinical data | |
---|---|
Trade names | Spiriva, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a604018 |
License data | |
Pregnancy category | |
Routes of administration | By mouth, inhalation by mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 19.5% (inhalation) |
Metabolism | Liver 25% (CYP2D6, CYP3A4) |
Elimination half-life | 5–6 days |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.234.575 |
Chemical and physical data | |
Formula | C19H22BrNO4S2 |
Molar mass | 472.41 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Tiotropium bromide, sold under the brand name Spiriva among others, is a long-acting bronchodilator (LAMA: long acting muscarinic antagonist) used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[10][11] Specifically it is used during periods of breathing difficulty to prevent them from getting worse, rather than to prevent them from happening.[10] It is used by inhalation through the mouth.[10] Onset typically begins within half an hour and lasts for 24 hours.[10]
Common side effects include a dry mouth, runny nose, upper respiratory tract infection, shortness of breath and headache.[10] Severe side effects may include angioedema, worsening bronchospasm, and QT prolongation.[10] Tentative evidence has not found harm during pregnancy, however, such use has not been well studied.[1] It is an anticholinergic medication and works by blocking acetylcholine action on smooth muscle.[10]
Tiotropium was patented in 1989, and approved for medical use in 2002.[12] It is on the World Health Organization's List of Essential Medicines.[13] In 2022, it was the 154th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[14][15]